Skip to content
Evigrade
CriticalVitamin K antagonist anticoagulants×Direct oral anticoagulants (factor Xa inhibitors)

Updated · Methodology

Mechanism

Edoxaban directly and reversibly inhibits clotting factor Xa and so reduces thrombin generation (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Acenocoumarol is a coumarin derivative and a vitamin K antagonist. It reduces the gamma-carboxylation of clotting factors II, VII, IX and X, and its effect lasts a little over 24 hours (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Edoxaban is contraindicated with any other anticoagulant, oral ones included, because of the increased risk of bleeding (EMA). Acenocoumarol is not named in this contraindication, but its own SmPC places it among the oral anticoagulants of the vitamin K antagonist group (AEMPS). Edoxaban itself prolongs the prothrombin time and the international normalised ratio (INR). With a vitamin K antagonist, it can raise the INR after an edoxaban dose by up to 46% (EMA).

Symptoms

Edoxaban increases the risk of bleeding, which can be severe or even fatal and can occur at any site (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Acenocoumarol can also cause severe bleeding, up to haemorrhagic and hypovolaemic shock, or fatal bleeding. Concomitant treatment is one of the risk factors for such bleeding (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If haemoglobin or blood pressure falls without explanation, look for a bleeding site (EMA).

Management

Edoxaban is contraindicated with any other anticoagulant, oral ones included, except when switching from one oral anticoagulant to another (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The US label does not recommend long-term use of edoxaban with other anticoagulants (edoxaban label, US Food and Drug Administration, FDA). The switching rules in the edoxaban SmPC cover vitamin K antagonists as a group. When switching from acenocoumarol, stop it and start edoxaban once the international normalised ratio (INR) is 2.5 or lower (EMA). When switching from edoxaban to acenocoumarol, keep anticoagulation continuous. With the oral option, patients on 60 mg take edoxaban 30 mg once daily together with a suitable dose of the vitamin K antagonist. Patients on 30 mg (creatinine clearance 15–50 mL/min, body weight 60 kg or less, or certain P-glycoprotein inhibitors) take 15 mg once daily (EMA). Do not give a loading dose of the vitamin K antagonist (EMA). The acenocoumarol SmPC also advises starting acenocoumarol without a loading dose (acenocoumarol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). During the first 14 days of co-administration, the edoxaban SmPC recommends measuring the INR at least three times, just before the daily edoxaban dose. Stop edoxaban once the INR reaches 2.0. After 14 days, the SmPC recommends stopping edoxaban and continuing to adjust the vitamin K antagonist dose to an INR of 2–3 (EMA). With the parenteral option, stop edoxaban and start a parenteral anticoagulant and the vitamin K antagonist at the time of the next scheduled edoxaban dose. Stop the parenteral anticoagulant once the INR is stable at 2.0 or higher (EMA). If severe bleeding occurs, stop edoxaban. There is no specific antidote, and vitamin K is not expected to affect edoxaban activity (EMA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Acenocoumarol

Other interactions with Edoxaban